 |
Our Management |
|
A management team with strength in knowledge, success and more than 150 combined years of experience in biotechnology.
|
|
| |
| H. Raymond Cairncross: |
Top |
| Co-Founder and CEO |
|
Mr. Cairncross has over 25 years of experience as a founder, Chairman, CEO, director of and counsel to high-tech and other companies. Ray formed the Seattle law firm of Cairncross & Hempelmann, specializing in business planning, corporate finance, and commercial transactions. As the firm's only Managing Partner, he developed and maintained a full practice focused on business planning, strategy, major commercial transactions, and financings. His first role as a founder was for Horizon Airlines where he was General Counsel and business strategist, negotiating the acquisition of Air Oregon and Cascade Airlines, leading to the sale of Horizon to Alaska Airlines.
Utilizing his legal and business expertise, Ray founded several high-tech companies including Ostex International, Inc., where he served as Chairman and CEO. The Seattle biotechnology company was based upon an innovative technology transfer arrangement with the University of Washington. He successfully negotiated complex domestic and international licensing and partnership arrangements, and equity and non-dilutive financings, taking Ostex public in the mid 1990's. Ray co-founded Omeros Medical Systems, Inc., a company with a successful pharmaceutical platform technology that delivers analgesic, anti-inflammatory, anti-spasm and/or anti-restenosis agents directly to the surgical site during arthroscopic, urologic, cardiovascular and general surgical procedures. As with Ostex, Omeros has developed strong intellectual property position and patent portfolio, along with an effective regulatory strategy. Ray co-founded Onconome, Inc. (formerly Tessera, Inc.) in 2001, has been its C.E.O. since 2003.
|
Ray received his BA degree from Stanford University and his JD degree from the University of Washington.
|
|
 |
| Randall Brock: |
Top |
| President |
|
Mr. Brock has over twenty-five years experience in the medical device and pharmaceutical industry in several roles including accounting and finance, manufacturing, human resources, and general research and development administration. Randy joined Onconome in July 2006.
Before joining Onconome, Randy was Controller for Nastech Pharmaceutical Company, Inc. While at Nastech, Randy worked with the CEO in negotiating a multi-million product licensing agreement with Pharmacia for the company's intranasal apomorphine product for sexual dysfunction. Prior to Nastech, Randy was Vice President, R&D Finance and Operations for Nycomed Amersham, Inc. an international pharmaceutical company with market leading contrast agent products in X-Ray CT, MRI and Nuclear Radiology. Prior to Nycomed, Randy was Sr. Vice President, Finance and Operations and CFO for Salutar, Inc., a development stage company discovering and developing in-vivo contrast agents for MRI. Salutar was sold to Nycomed for an 8 fold return on venture funding. Previously to his years at Salutar, Randy held top manufacturing positions at International Diagnostic Technologies, Inc., and Smith Kline Instruments, Inc., both manufacturers of in-vitro diagnostic products for blood chemistries and infectious diseases.
|
Randy received his B.S. degree in Medical Microbiology from California State University, Chico and his MBA from the University of Santa Clara.
|
|
|
|
|
|
|
